Abstract
Testicular germ cell tumors are chemosensitive with very high cure-rates even in the metastatic setting. However, patients with platinum-refractory and relapsing tumors after autologous stem cell transplant have very poor outcomes despite salvage treatments, and with no effective alternative therapies. Immunotherapy, notably with PD-1 inhibitors, has proven to be very effective in treating various solid tumors. This review summarizes the experience with anti-PD-1 agents (pembrolizumab,nivolumab) in the treatment of testicular germ cell tumor relapsing after multiple lines of treatment, and exposes future trials evaluating newer checkpoint inhibitors in this setting.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 533-541 |
| Number of pages | 9 |
| Journal | Future Oncology |
| Volume | 15 |
| Issue number | 5 |
| DOIs | |
| State | Published - Feb 2019 |
| Externally published | Yes |
Keywords
- Germ cell
- Immune checkpoint inhibitors
- Immunotherapy
- PD-L1
- Platinum-refractory
- Testicular cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research